Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.645 EUR | +0.21% | -0.98% | -54.68% |
May. 06 | EVOTEC : Warburg Research reiterates its Buy rating | ZD |
May. 03 | EVOTEC : RBC reiterates its Buy rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-54.68% | 1.83B | A- | ||
+23.37% | 46.71B | B- | ||
+48.83% | 41.8B | A | ||
-0.94% | 41.52B | B | ||
-5.86% | 29.55B | C | ||
+11.29% | 25.78B | B- | ||
-20.92% | 19.26B | B | ||
+3.20% | 12.14B | B+ | ||
-2.67% | 12.08B | C+ | ||
+30.23% | 11.98B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings Evotec SE